1800-272-662
Shopping Cart 0
countryflagAU
Login

Globus Medical

Healthcare US GMED

86.65USD
-1.16(1.32%)

Last update at 2026-03-10T20:18:00Z

Day Range

86.1388.51
LowHigh

52 Week Range

43.3980.04
LowHigh

Fundamentals

  • Previous Close 87.81
  • Market Cap6976.46M
  • Volume972066
  • P/E Ratio34.44
  • Dividend Yield-%
  • EBITDA347.26M
  • Revenue TTM1226.44M
  • Revenue Per Share TTM11.84
  • Gross Profit TTM 759.12M
  • Diluted EPS TTM1.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 243.02M 180.41M 125.90M 189.95M 188.60M
Minority interest - - - - -
Net income 190.17M 149.19M 102.28M 155.21M 156.47M
Selling general administrative 432.12M 408.15M 354.76M 354.76M 311.59M
Selling and marketing expenses - - - - -
Gross profit 759.12M 718.88M 571.58M 605.39M 553.56M
Reconciled depreciation 68.25M 69.87M 62.87M 52.73M 41.63M
Ebit 227.95M 171.95M 111.43M 171.99M 184.44M
Ebitda 313.82M 289.05M 182.66M 229.96M 226.07M
Depreciation and amortization 85.87M 117.10M 71.23M 57.98M 41.63M
Non operating income net other 15.07M 8.45M 14.47M - 19.28M
Operating income 227.95M 171.95M 111.43M 171.99M 169.32M
Other operating expenses 786.59M 763.24M 673.57M 608.61M 536.09M
Interest expense 14.23M 9.30M 13.95M -17.40600M 13.28M
Tax provision 52.85M 31.22M 23.61M 34.74M 32.13M
Interest income - - - 17.48M 13.64M
Net interest income 14.23M 9.30M 13.95M 17.41M 13.28M
Extraordinary items - - - - -
Non recurring 8.30M 22.91M 4.04M - 7.56M
Other items - - - - -
Income tax expense 52.85M 31.22M 23.61M 34.74M 32.13M
Total revenue 1022.84M 958.10M 789.04M 785.37M 712.97M
Total operating expenses 522.87M 524.02M 456.11M 428.64M 376.68M
Cost of revenue 263.73M 239.22M 217.46M 179.97M 159.41M
Total other income expense net 15.07M 8.45M 14.47M 17.96M 11.72M
Discontinued operations - - - - -
Net income from continuing ops 190.17M 149.19M 102.28M 155.21M 156.47M
Net income applicable to common shares 190.17M 149.19M 102.28M 155.21M 156.47M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2076.13M 1957.26M 1679.48M 1532.08M 1300.67M
Intangible assets 63.57M 68.66M 86.95M 78.81M 87.32M
Earning assets - - - - -
Other current assets 21.00M 18.42M 17.77M 17.24M 15.39M
Total liab 229.75M 215.88M 173.19M 129.62M 115.15M
Total stockholder equity 1846.37M 1741.39M 1506.30M 1402.45M 1185.52M
Deferred long term liab 1.78M 4.31M 6.20M - 8.11M
Other current liab 109.00M 11.77M 5.78M 6.73M 63.12M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 1239.95M 1194.27M 1045.08M 1047.93M 892.72M
Other liab 70.55M 75.71M 52.40M 17.08M 19.04M
Good will 197.47M 179.71M 156.72M 128.78M 123.73M
Other assets 92.16M 60.83M 209.83M 25.19M 23.94M
Cash 150.47M 193.07M 239.40M 195.72M 139.75M
Cash and equivalents - - - - -
Total current liabilities 159.20M 140.16M 120.79M 111.40M 96.12M
Current deferred revenue 14.10M 12.03M 8.12M 5.40M 2.60M
Net debt -150.46600M -193.06900M -239.39700M -195.72400M -139.74700M
Short term debt - 94.41M 88.69M 74.66M 4.51M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 630.95M 553.79M 457.16M 357.32M 299.87M
Property plant equipment 243.73M 221.08M 216.88M 202.32M 171.87M
Total current assets 983.34M 864.52M 821.76M 687.47M 630.68M
Long term investments 495.85M 562.48M 358.52M 409.51M 263.12M
Net tangible assets 1585.33M 1493.02M 1262.63M 1194.87M 974.46M
Short term investments 295.59M 250.38M 187.34M 115.76M 199.94M
Net receivables 217.31M 165.65M 148.10M 162.42M 144.36M
Long term debt - - - - -
Inventory 298.98M 237.00M 229.15M 196.31M 131.25M
Accounts payable 36.10M 21.95M 18.20M 24.61M 25.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -24.63000M -6.77200M 3.96M -2.89800M -7.17200M
Additional paid in capital - - - - -
Common stock total equity 0.10M 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity 1239.95M 1194.27M 1045.08M - 892.72M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 43.31M 36.33M 32.04M 21.74M 10.36M
Deferred long term asset charges - - - - 13.58M
Non current assets total 1092.78M 1092.75M 857.72M 844.61M 669.99M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.88000M -284.55300M -20.18100M -45.73200M -123.50500M
Change to liabilities 17.62M 26.79M 12.91M 0.77M 10.80M
Total cashflows from investing activities -110.36200M -375.93900M -117.32200M -140.28100M -193.02700M
Net borrowings - - - - -
Total cash from financing activities -109.96200M 54.15M -38.66300M 24.44M 32.57M
Change to operating activities -4.20500M 11.72M 6.52M -5.22000M 7.23M
Net income 190.17M 149.19M 102.28M 155.21M 156.47M
Change in cash -42.60300M -46.32800M 43.67M 55.98M 20.93M
Begin period cash flow 193.07M 239.40M 195.72M 139.75M 118.82M
End period cash flow 150.47M 193.07M 239.40M 195.72M 139.75M
Total cash from operating activities 178.47M 276.27M 198.79M 171.97M 181.64M
Issuance of capital stock - 63.50M 72.32M 31.04M 39.31M
Depreciation 68.25M 69.87M 62.87M 52.73M 41.63M
Other cashflows from investing activities -31.43500M -34.48800M -33.48300M -69.53100M -9.82500M
Dividends paid - - - - -
Change to inventory -61.74500M -11.97100M -50.11100M -50.01800M -31.38200M
Change to account receivables -50.84300M -25.89500M 10.70M -18.30600M -21.78900M
Sale purchase of stock -144.49300M 63.50M -104.66900M 31.04M 39.31M
Other cashflows from financing activities -7.18500M -9.34900M -6.31600M -6.59700M -6.73900M
Change to netincome 22.57M 71.90M 71.34M 37.48M 31.73M
Capital expenditures 74.05M 56.90M 63.66M 70.75M 59.70M
Change receivables -50.84300M -25.89500M 10.70M - -21.78900M
Cash flows other operating -12.93900M -6.38800M -11.78800M - -7.49600M
Exchange rate changes - - - - -0.25600M
Cash and cash equivalents changes -41.85600M -45.51800M 42.81M - 20.93M
Change in working capital -105.26200M -17.25200M -37.59000M -73.44400M -49.86800M
Stock based compensation 32.81M 30.59M 27.07M 26.09M 21.90M
Other non cash items 14.72M 61.50M 48.49M 7.09M 10.54M
Free cash flow 104.42M 219.38M 135.13M 101.22M 121.95M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GMED
Globus Medical		 -1.16 1.32% 86.65 34.44 19.19 5.69 1.67 5.73 21.42
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical

2560 General Armistead Avenue, Audubon, PA, United States, 19403

Key Executives

Name Title Year Born
Mr. David C. Paul Co-Founder & Exec. Chairman 1967
Mr. Daniel T. Scavilla Pres, CEO & Director 1965
Mr. Keith W. Pfeil Sr. VP & CFO 1979
Ms. Kelly G. Huller Esq. Sr. VP, Gen. Counsel & Sec. 1972
Mr. Brian J. Kearns Sr. VP of Bus. Devel. & Investor Relations 1967
Mr. A. Brett Murphy Exec. VP of International Sales 1965
Mr. Steven M. Payne VP & Controller 1971
Mr. Mike Reeder Exec. Officer NA
Mr. Richard Holifield Exec. Officer NA
Mr. John Dowling Exec. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.